US20220218640A1 - Amino acid delivery system - Google Patents
Amino acid delivery system Download PDFInfo
- Publication number
- US20220218640A1 US20220218640A1 US17/572,368 US202217572368A US2022218640A1 US 20220218640 A1 US20220218640 A1 US 20220218640A1 US 202217572368 A US202217572368 A US 202217572368A US 2022218640 A1 US2022218640 A1 US 2022218640A1
- Authority
- US
- United States
- Prior art keywords
- vitamin
- delivery system
- nutrients
- amino acid
- leucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
Definitions
- the present invention relates generally to dietary supplement systems, and more specifically, to an amino acid delivery system, that contains a complete amount of Leucine, Isoleucine, and Valine along with other supporting nutrients in a single dose.
- Dietary supplement systems are well known in the art and are effective means to augment the food that people eat to provide a spectrum of nutrients to the person's body that are is naturally found in the food that is consumed.
- Common dietary supplement systems include pills, drinks, and solutions that have either a single vitamin or a cocktail of vitamins that are either ingested or injected into the body. Those that are ingested are dissolved in the stomach and transferred to the bloodstream. Those that are injected are received in an aqueous form in the bloodstream directly. Once in the bloodstream the vitamins are used by the body.
- cocktail vitamins have many vitamins combined into a single dose.
- the vitamins are each beneficial to the body. When combined some of the vitamins will have negative interactions with others limiting the effectiveness of the dose.
- FIG. 1 is a list of ingredients of an amino acid delivery system in accordance with a preferred embodiment of the present application.
- the system and method of use in accordance with the present application overcomes one or more of the above-discussed problems commonly associated with conventional dietary supplement systems. Specifically, the present invention delivers a broad range of nutrients that synergistically nourish the body.
- FIG. 1 depicts a list of ingredients in accordance with the present application. It will be appreciated that system 101 overcomes one or more of the above-listed problems commonly associated with conventional dietary supplement systems.
- system 101 includes carrier 123 such as water, that contains leucine 103 , isoleucine 105 , valine 107 , vitamin C 109 , vitamin B3 111 , vitamin B5 113 , vitamin B6 115 , vitamin B7 117 , vitamin B9 119 , and vitamin B12 121 .
- carrier 123 such as water, that contains leucine 103 , isoleucine 105 , valine 107 , vitamin C 109 , vitamin B3 111 , vitamin B5 113 , vitamin B6 115 , vitamin B7 117 , vitamin B9 119 , and vitamin B12 121 .
- This bodyweight does not account for or represent larger individuals such as college football players or National Football League size athletes. It does fulfill some athletes such as wrestlers, hockey, boxing, UFC fighters, and soccer players.
- the preferred embodiment contains 100% of the RDA for a person of this weight.
- the essential amino acids leucine 103 , isoleucine 105 , valine 107 increase the biosynthesis within the body, aid in transportation of other substances, and facilitate the function of the process therein. These are termed essential amino acids because the body does not make them, but they are necessary. This requires that they be consumed or otherwise obtained from outside the body.
- This embodiment provides all of the RDA amounts of these nutrients in a single dose of an average size person.
- a double dose provides nearly a complete amount to a larger person.
- the ingredients within the amino acid delivery system 101 are scientifically proven to reduce the severity of brain injury in animal models and have been shown to enhance the recovery from brain injury in humans. This is vital particularly for athletes who have a higher risk of head injuries.
- Leucine—for the average American male of 90 kg the invention fulfills 93% of RDA. Larger athletes of say 350 lbs would need 6.7 gms of Leucine to be at RDA levels of 42 mg/kg. 42 mg ⁇ 160 kg 6,681 mg. Thus, two doses of the invention (AminoHeal) (7.0 gms) cover 100% of the RDA without considering any daily food intake.
- AmoHeal 7.0 gms
- B5 Pantothenic acid 5 mg:100% of 5 mg RDA required for oxidative metabolism as well as amino acid, cholesterol and neurotransmitter synthesis (3)
- B6 Pyridoxine 10 mg:750% of 1.3 mg RDA a necessary cofactor for amino acid metabolism and synthesis of neurotransmitters including GABA.
- Branched-Chain Aminotransferase BCAT is dependent on B6!!! Deficiency leads to downregulation of GABA and serotonin synthesis leading to removal of the inhibitory effects of GABA thus allowing a hyperexcitability state of excess Glutamate (3).
- *Upper consumption limit set at 100 mg/day based on its ability to cause reversible sensory neuropathy at daily doses over 1000 mg/day for long periods (3).
- B7 Biotin 30 mg:100% of 30 mg RDA plays a key role in glucose metabolism within the brain. Hyperglycemia occurs in the initial state of TBI and can continue for weeks.
- B9 Folate 400 mcg:100% of RDA essential for DNA/RNA synthesis and repair as well as protein synthesis within the brain.
- B12 Cyancobalamin 50 mcg:2000% of RDA 2.4 mcg works in concert with folate and is essential in rapidly developing tissue such as fetal neuronal growth or in brain injury/repair (3).
- AminoHeal The ingredients within AminoHeal are scientifically proven to reduce the severity of brain injury in animal models and has shown to enhance recovery from brain injury in humans.
- the essential amino acid combination in AminoHeal is also proven to enhance muscle growth and recovery.
- the key ingredients of AminoHeal are considered ESSENTIAL (your body will not produce them, they must be ingested) for muscle and brain function. These statements have not been evaluated by the Food and Drug administration. This product is not intended to diagnose, treat, cure or prevent any disease.
- Recommendations would be for any athlete who is entering a contact sport, practice or game. Drink or take one dose of AminoHeal 30 minutes prior to starting a game or practice. Research has shown Leucine levels peak in about 30 minutes after ingestion. Should the athlete suffer a significant head injury i.e., concussion, he is removed from the game/practice and should immediately ingest another drink or dose of AminoHeal. The traumatic brain injury cascade starts immediately after the injury with an overwhelming release of Glutamate. Leucine and other ingredients within AminoHeal will combat the initial cascade as well as the secondary injury that follows. The injured athlete should ingest Aminoheal twice daily until symptoms resolve and be under the supervision of a physician.
- AminoHeal Recommendations for muscle growth and repair in noncontact sport athletes or in patients recovering from surgery/injury.
- One AminoHeal dose will provide almost 100% of the RDA for essential amino acids needed for muscle growth and repair. AminoHeal is recommended to be used as a supplement to a healthy diet.
Abstract
An amino acid delivery system contains the essential amino acids, leucine, isoleucine, and valine in a complete amount that is indigestible in a single dose. The delivery system also includes other beneficial nutrients like vitamin C and vitamin B. Double doses accommodate larger bodies. The amino acids are combined in ratios that allow them to be mutually supportive. This combination ratio allows the body to absorb and use the nutrients at a greater rate. This blend of nutrients is indicated to reduce/prevent traumatic brain injury when taken prior to contact sports and enhance recovery after any form of traumatic brain injury.
Description
- The present invention relates generally to dietary supplement systems, and more specifically, to an amino acid delivery system, that contains a complete amount of Leucine, Isoleucine, and Valine along with other supporting nutrients in a single dose.
- Dietary supplement systems are well known in the art and are effective means to augment the food that people eat to provide a spectrum of nutrients to the person's body that are is naturally found in the food that is consumed. Common dietary supplement systems include pills, drinks, and solutions that have either a single vitamin or a cocktail of vitamins that are either ingested or injected into the body. Those that are ingested are dissolved in the stomach and transferred to the bloodstream. Those that are injected are received in an aqueous form in the bloodstream directly. Once in the bloodstream the vitamins are used by the body.
- One of the problems associated with common dietary supplement systems is their limited efficiency. For example, a vitamin shot of vitamin B improves the body's organs and systems that need it but neglects the other organs and systems.
- Additionally, cocktail vitamins have many vitamins combined into a single dose. The vitamins are each beneficial to the body. When combined some of the vitamins will have negative interactions with others limiting the effectiveness of the dose.
- Accordingly, although great strides have been made in the area of dietary supplement systems, many shortcomings remain.
- The novel features believed characteristic of the embodiments of the present application are set forth in the appended claims. However, the embodiments themselves, as well as a preferred mode of use, and further objectives and advantages thereof, will best be understood by reference to the following detailed description when read in conjunction with the accompanying drawings, wherein:
-
FIG. 1 is a list of ingredients of an amino acid delivery system in accordance with a preferred embodiment of the present application. - While the system and method of use of the present application is susceptible to various modifications and alternative forms, specific embodiments thereof have been shown by way of example in the drawings and are herein described in detail. It should be understood, however, that the description herein of specific embodiments is not intended to limit the invention to the particular embodiment disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present application as defined by the appended claims.
- Illustrative embodiments of the system and method of use of the present application are provided below. It will of course be appreciated that in the development of any actual embodiment, numerous implementation-specific decisions will be made to achieve the developer's specific goals, such as compliance with system-related and business-related constraints, which will vary from one implementation to another. Moreover, it will be appreciated that such a development effort might be complex and time-consuming, but would nevertheless be a routine undertaking for those of ordinary skill in the art having the benefit of this disclosure.
- The system and method of use in accordance with the present application overcomes one or more of the above-discussed problems commonly associated with conventional dietary supplement systems. Specifically, the present invention delivers a broad range of nutrients that synergistically nourish the body. These and other unique features of the system and method of use are discussed below and illustrated in the accompanying drawings.
- The system and method of use will be understood, both as to its structure and operation, from the accompanying drawings, taken in conjunction with the accompanying description. Several embodiments of the system are presented herein. It should be understood that various components, parts, and features of the different embodiments may be combined together and/or interchanged with one another, all of which are within the scope of the present application, even though not all variations and particular embodiments are shown in the drawings. It should also be understood that the mixing and matching of features, elements, and/or functions between various embodiments is expressly contemplated herein so that one of ordinary skill in the art would appreciate from this disclosure that the features, elements, and/or functions of one embodiment may be incorporated into another embodiment as appropriate, unless described otherwise.
- The preferred embodiment herein described is not intended to be exhaustive or to limit the invention to the precise form disclosed. It is chosen and described to explain the principles of the invention and its application and practical use to enable others skilled in the art to follow its teachings.
- Referring now to the drawings wherein like reference characters identify corresponding or similar elements throughout the several views,
FIG. 1 depicts a list of ingredients in accordance with the present application. It will be appreciated thatsystem 101 overcomes one or more of the above-listed problems commonly associated with conventional dietary supplement systems. - In the contemplated embodiment,
system 101 includescarrier 123 such as water, that containsleucine 103,isoleucine 105,valine 107,vitamin C 109,vitamin B3 111,vitamin B5 113,vitamin B6 115,vitamin B7 117,vitamin B9 119, andvitamin B12 121. - The average male and many females weigh 154 lbs (70 kg) and has a recommended dietary allowance (RDA) as follows:
leucine 103 42 mg/kg=2940 mg; Isoleucine 19 mg/kg=1330 mg; Valine 24 mg/kg=1680 mg. This bodyweight does not account for or represent larger individuals such as college football players or National Football League size athletes. It does fulfill some athletes such as wrestlers, hockey, boxing, UFC fighters, and soccer players. The preferred embodiment contains 100% of the RDA for a person of this weight. The essentialamino acids leucine 103,isoleucine 105,valine 107 increase the biosynthesis within the body, aid in transportation of other substances, and facilitate the function of the process therein. These are termed essential amino acids because the body does not make them, but they are necessary. This requires that they be consumed or otherwise obtained from outside the body. - For those of a larger weight say, 197.8 lbs (90 kg) the RDA for these essential amino acids is a as follows: Leucine=3780 mg; Isoleucine=1710 mg; Valine=2160 mg.
- The contemplated embodiment includes the following:
-
-
Leucine 103 at 3500 mg -
Isoleucine 105 at 1750 mg - Valine 107 at 1750 mg
- Vitamin C 109 at 200 mg
- Vitamin B3 111 at 16 mg
- Vitamin B5 113 at 5 mg
- Vitamin B6 115 at 10 mg
- Vitamin B7 117 at 30 mg
- Vitamin B9 119 at 400 mcg
-
Vitamin B12 121 at 50 mcg
-
- This embodiment provides all of the RDA amounts of these nutrients in a single dose of an average size person. A double dose provides nearly a complete amount to a larger person.
- The ingredients within the amino
acid delivery system 101 are scientifically proven to reduce the severity of brain injury in animal models and have been shown to enhance the recovery from brain injury in humans. This is vital particularly for athletes who have a higher risk of head injuries. - It should be appreciated that one of the unique features believed characteristic of the present application is that a single dose of the
acid delivery system 101 maintains the 2:1:1 ratio of these essential amino acids to improve the biosynthesis of the body. - It will be appreciated that Leucine—for the average American male of 90 kg the invention fulfills 93% of RDA. Larger athletes of say 350 lbs would need 6.7 gms of Leucine to be at RDA levels of 42 mg/kg. 42 mg×160 kg=6,681 mg. Thus, two doses of the invention (AminoHeal) (7.0 gms) cover 100% of the RDA without considering any daily food intake. Regarding Isoleucine—1750 mg for average American (90 kg male) fulfills 100% of the RDA and maintains the 2:1:1 suggested ratio of Leucine to Isoleucine/Valine. For Valine—1750 mg fulfills 81% of the RDA for an average 90 kg male and maintains the 2:1:1 ratio. Vitamin C −200 mg: >200% of 90 mg RDA, tolerable upper intake dose per NIH guidelines 2000 mg/day (1). Essential for oxidative stress in TBI and has been recommended in TBI to mitigate secondary brain injury (2). B3 Niacin—16 mg:100% of 16 mg RDA essential for oxidative stress, modulates inflammatory reactions which occur in TBI. *Upper consumption limit of 35 mg based on its ability to cause skin flushing at doses>100 mg/day (3). B5 Pantothenic acid—5 mg:100% of 5 mg RDA required for oxidative metabolism as well as amino acid, cholesterol and neurotransmitter synthesis (3) B6 Pyridoxine—10 mg:750% of 1.3 mg RDA a necessary cofactor for amino acid metabolism and synthesis of neurotransmitters including GABA. Branched-Chain Aminotransferase BCAT is dependent on B6!!! Deficiency leads to downregulation of GABA and serotonin synthesis leading to removal of the inhibitory effects of GABA thus allowing a hyperexcitability state of excess Glutamate (3). *Upper consumption limit set at 100 mg/day based on its ability to cause reversible sensory neuropathy at daily doses over 1000 mg/day for long periods (3). B7 Biotin—30 mg:100% of 30 mg RDA plays a key role in glucose metabolism within the brain. Hyperglycemia occurs in the initial state of TBI and can continue for weeks. B9 Folate—400 mcg:100% of RDA essential for DNA/RNA synthesis and repair as well as protein synthesis within the brain. Works in concert with B12 (3). *Upper consumption limit set at 1000 mcg due to its ability at high doses to mask B12 deficiency (3). B12 Cyancobalamin—50 mcg:2000% of RDA 2.4 mcg works in concert with folate and is essential in rapidly developing tissue such as fetal neuronal growth or in brain injury/repair (3). *Only three (B3, B6, B9) of the eight B vitamins have been ascribed a daily upper limit of consumption with the remainder being safe at any dose. Even at THREE AminoHeal doses or drinks a day (which is NOT recommended) only B9 is slightly above (200 mcg) the daily recommended dose. The daily upper limits of folate literature is based on that long-term usage of high-dose folate may mask a B12 deficiency (3). A US national survey, NHANES 2007-2010, which surveyed 16,444 individuals >4 years of age, reported a high prevalence of inadequacies for multiple micronutrients. The prevalence of inadequacies was low for all of the B vitamins and almost 40% were low for vitamin C (4). Based on the aforementioned literature, the average American could drink one dose of AminoHeal a day and supply themselves with close to 100% of their daily essential amino acid requirements as well as 100% of Vitamins C, B3, B5, B6, B7, B9, B12. Since AminoHeal is a supplement drink not a meal replacement, we can assume the athlete is adding AminoHeal to their normal high protein diet, further ensuring that their muscles and brain are being supplied with the proper nutrients to function as well as maximize their ability to recover and heal from injury. AminoHeal was designed by a Board-Certified Neurosurgeon and Ph.D. Biochemists in an effort to reduce the severity of initial traumatic brain injury (concussion) as well as enhance recovery from traumatic brain injury. The ingredients within AminoHeal are scientifically proven to reduce the severity of brain injury in animal models and has shown to enhance recovery from brain injury in humans. The essential amino acid combination in AminoHeal is also proven to enhance muscle growth and recovery. The key ingredients of AminoHeal are considered ESSENTIAL (your body will not produce them, they must be ingested) for muscle and brain function. These statements have not been evaluated by the Food and Drug administration. This product is not intended to diagnose, treat, cure or prevent any disease.
- Recommendations would be for any athlete who is entering a contact sport, practice or game. Drink or take one dose of AminoHeal 30 minutes prior to starting a game or practice. Research has shown Leucine levels peak in about 30 minutes after ingestion. Should the athlete suffer a significant head injury i.e., concussion, he is removed from the game/practice and should immediately ingest another drink or dose of AminoHeal. The traumatic brain injury cascade starts immediately after the injury with an overwhelming release of Glutamate. Leucine and other ingredients within AminoHeal will combat the initial cascade as well as the secondary injury that follows. The injured athlete should ingest Aminoheal twice daily until symptoms resolve and be under the supervision of a physician. Recommendations for muscle growth and repair in noncontact sport athletes or in patients recovering from surgery/injury. One AminoHeal dose will provide almost 100% of the RDA for essential amino acids needed for muscle growth and repair. AminoHeal is recommended to be used as a supplement to a healthy diet.
- The particular embodiments disclosed above are illustrative only, as the embodiments may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. It is therefore evident that the particular embodiments disclosed above may be altered or modified, and all such variations are considered within the scope and spirit of the application. Accordingly, the protection sought herein is as set forth in the description. Although the present embodiments are shown above, they are not limited to just these embodiments, but are amenable to various changes and modifications without departing from the spirit thereof.
Claims (1)
1. An amino acid delivery system comprising:
a carrier;
leucine;
isoleucine;
valine;
vitamin C;
vitamin B3;
vitamin B5;
vitamin B6;
vitamin B7;
vitamin B9; and
vitamin B12;
wherein the leucine, isoleucine, and valine are combined at a 2:1:1 ratio.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/572,368 US20220218640A1 (en) | 2021-01-14 | 2022-01-10 | Amino acid delivery system |
PCT/US2022/020329 WO2023132847A1 (en) | 2021-01-14 | 2022-03-15 | Compositions and methods for prevention and reduction of traumatic brain injury |
US17/696,723 US20220218642A1 (en) | 2021-01-14 | 2022-03-16 | Compositions And Methods For Prevention And Reduction Of Traumatic Brain Injury |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163137507P | 2021-01-14 | 2021-01-14 | |
US17/572,368 US20220218640A1 (en) | 2021-01-14 | 2022-01-10 | Amino acid delivery system |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/696,723 Continuation US20220218642A1 (en) | 2021-01-14 | 2022-03-16 | Compositions And Methods For Prevention And Reduction Of Traumatic Brain Injury |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220218640A1 true US20220218640A1 (en) | 2022-07-14 |
Family
ID=82323219
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/572,368 Abandoned US20220218640A1 (en) | 2021-01-14 | 2022-01-10 | Amino acid delivery system |
US17/696,723 Pending US20220218642A1 (en) | 2021-01-14 | 2022-03-16 | Compositions And Methods For Prevention And Reduction Of Traumatic Brain Injury |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/696,723 Pending US20220218642A1 (en) | 2021-01-14 | 2022-03-16 | Compositions And Methods For Prevention And Reduction Of Traumatic Brain Injury |
Country Status (2)
Country | Link |
---|---|
US (2) | US20220218640A1 (en) |
WO (1) | WO2023132847A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4687782A (en) * | 1984-12-10 | 1987-08-18 | Nutri-Fuels Systems, Inc. | Nutritional composition for enhancing skeletal muscle adaptation to exercise training |
US5866537A (en) * | 1995-05-19 | 1999-02-02 | Farmila-Farmaceutici Milano S.R.L. | Pharmaceutical and/or dietetic compositions with antioxidant activity containing carnosine or derivatives and branched amino acids |
US8952040B2 (en) * | 2010-08-06 | 2015-02-10 | Maoxing Yue | Pharmaceutical composition for treating coagulation disorder hemorrhage and method using the same |
WO2016112170A1 (en) * | 2015-01-07 | 2016-07-14 | Corr-Jensen Inc. | Compositions and methods for enhancing athletic performance |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160058726A1 (en) * | 2013-04-16 | 2016-03-03 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of brain injury |
US20180133185A1 (en) * | 2016-11-11 | 2018-05-17 | The Children's Hospital Of Philadelphia | Compositions and Methods for the Improvement of Memory |
US11617731B2 (en) * | 2017-04-28 | 2023-04-04 | Axcella Health, Inc. | Amino acid compositions and their use for the treatment of traumatic brain injury |
TW201919602A (en) * | 2017-08-14 | 2019-06-01 | 美商胺細拉健康公司 | Compositions and methods for the treatment of neuronal injury |
-
2022
- 2022-01-10 US US17/572,368 patent/US20220218640A1/en not_active Abandoned
- 2022-03-15 WO PCT/US2022/020329 patent/WO2023132847A1/en unknown
- 2022-03-16 US US17/696,723 patent/US20220218642A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4687782A (en) * | 1984-12-10 | 1987-08-18 | Nutri-Fuels Systems, Inc. | Nutritional composition for enhancing skeletal muscle adaptation to exercise training |
US5866537A (en) * | 1995-05-19 | 1999-02-02 | Farmila-Farmaceutici Milano S.R.L. | Pharmaceutical and/or dietetic compositions with antioxidant activity containing carnosine or derivatives and branched amino acids |
US8952040B2 (en) * | 2010-08-06 | 2015-02-10 | Maoxing Yue | Pharmaceutical composition for treating coagulation disorder hemorrhage and method using the same |
WO2016112170A1 (en) * | 2015-01-07 | 2016-07-14 | Corr-Jensen Inc. | Compositions and methods for enhancing athletic performance |
Non-Patent Citations (1)
Title |
---|
Bifari et al. "Branched-Chain Amino Acids Differently Modulate Catabolic and Anabolic States in Mammals: A Pharmacological Point of View". British Journal of Pharmacology. 2017 Jun; 174(11):1366-1377. (Year: 2017) * |
Also Published As
Publication number | Publication date |
---|---|
US20220218642A1 (en) | 2022-07-14 |
WO2023132847A1 (en) | 2023-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5925377A (en) | Dietary supplement composition | |
AU2010274125B2 (en) | Methods of attenuating the loss of functional status | |
US7674482B2 (en) | Method and compositions for potentiating pharmaceuticals with amino acid based medical foods | |
US8901109B2 (en) | Quercetin-containing compositions | |
US7572462B2 (en) | Peri-operative and peri-procedure nutritional supplementation | |
US6159505A (en) | Compositions for the treatment of migraine, containing potassium, magnesium and pyridoxine | |
US20050196434A1 (en) | Pharmaceutical composition and method for the transdermal delivery of magnesium | |
US20060239987A1 (en) | Nutritional composition and methods of making and using same | |
US20100190739A1 (en) | Rapidly Dissolving Vitamin Formulation and Methods of Using the Same | |
US20030104107A1 (en) | Energy drink formula and method | |
US11464753B2 (en) | Composition for treatment of neurodegenerative disease | |
US20150044302A1 (en) | Compositions and methods for promoting appetite suppression using alkali metals | |
US20220218640A1 (en) | Amino acid delivery system | |
US20110274791A1 (en) | Multivitamin/mineral formulation to combat the effects of environmental stress; improved immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement | |
JP6117031B2 (en) | Back pain prevention and / or improvement agent, food and drink for back pain prevention | |
US6932987B1 (en) | Chemical composition and method for enhancing metabolism | |
JPH09157163A (en) | Amino acid composition and its ingestion | |
Leutholtz et al. | Optimizing nutrition for exercise and sport | |
US20080108698A1 (en) | Nutrient Supplement and Use of the Same | |
JP2015189705A (en) | Backache preventing and/or improving agent comprising components controlled to be sustainedly released | |
US20140242202A1 (en) | Composition for Reducing Side- and After-Effects of Cancer Treatment | |
US20060029641A1 (en) | Calcium and magnesium nutritional supplement | |
US8685918B1 (en) | Weight loss regimen comprising enteral and oral feeding segments effective for the treatment of obesity | |
UA104500U (en) | Functional food product | |
Dharmananda | Amino Acid Supplements I: Glutamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |